Regarding the impact on Sozinibercept trail, my understanding is that its mechanism of action differs from that of Eylea. Given this distinction, is it more of a competitive concern, or do they merely coexist within the trial framework? The decline in the share price suggests that this situation may not be good for OPT.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-53
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.3¢ |
Change
0.003(0.66%) |
Mkt cap ! $464.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.5¢ | $167.5K | 440.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 122320 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 26881 | 4 |
View Market Depth
| Last trade - 13.40pm 19/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |